Literature DB >> 19726566

Late-night and low-dose dexamethasone-suppressed cortisol in saliva and serum for the diagnosis of cortisol-secreting adrenal adenomas.

Timo Deutschbein1, Nicole Unger, Jakob Hinrichs, Martin K Walz, Klaus Mann, Stephan Petersenn.   

Abstract

OBJECTIVE: In patients with adrenal incidentalomas, hormonally active masses need to be considered, particularly cortisol-producing adenomas (CPA), aldosterone-producing adenomas, and pheochromocytomas. The screening for hypercortisolism relies on confirming excess cortisol secretion and insufficient suppression after dexamethasone. Because of its high correlation with free cortisol and its stress-free collection, salivary cortisol (SaC) may offer advantages over serum cortisol (SeC). We evaluated the value of SaC and SeC for the diagnosis of CPA. Design Comparative study between 2001 and 2006.
METHODS: Thirty-eight patients with confirmed CPA were compared with 18 healthy subjects as well as 48 control patients suffering from aldosterone-producing adenomas (n=13), pheochromocytomas (n=16), or nonfunctioning adenomas (n=19). Sampling of saliva and serum was performed at 2300 and at 0800 h following low-dose dexamethasone suppression. Receiver operating characteristics analysis was used to calculate thresholds with at least 95% sensitivity for CPA.
RESULTS: Regarding the cutoffs for late-night cortisol, SaC (4.8 nmol/l, sensitivity 97%, specificity 69%) was slightly more specific than SeC (115 nmol/l, sensitivity 97%, specificity 63%). In contrast, the cutoff for dexamethasone-suppressed SaC (3.7 nmol/l, sensitivity 97%, specificity 83%) was slightly less specific than SeC (94 nmol/l, sensitivity 97%, specificity 88%). However, the latter cutoffs demonstrated greater specificity when compared with the cutoffs for late-night cortisol.
CONCLUSION: The diagnostic accuracy of SaC is as good as SeC. Owing to its higher specificity, dexamethasone-suppressed cortisol is preferable to late-night cortisol when screening for Cushing's syndrome in patients with adrenal incidentalomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19726566     DOI: 10.1530/EJE-09-0517

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing's syndrome.

Authors:  Zhanna E Belaya; Alexander V Iljin; Galina A Melnichenko; Liudmila Y Rozhinskaya; Natalia V Dragunova; Larisa K Dzeranova; Svetlana A Butrova; Ekaterina A Troshina; Ivan I Dedov
Journal:  Endocrine       Date:  2012-03-25       Impact factor: 3.633

Review 2.  Cushing's syndrome: diagnosis and surveillance using salivary cortisol.

Authors:  Hershel Raff
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 3.  Update on late-night salivary cortisol for the diagnosis of Cushing's syndrome: methodological considerations.

Authors:  Hershel Raff
Journal:  Endocrine       Date:  2013-07-10       Impact factor: 3.633

4.  First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS.

Authors:  F Ceccato; G Antonelli; A C Frigo; D Regazzo; M Plebani; M Boscaro; C Scaroni
Journal:  J Endocrinol Invest       Date:  2017-02-28       Impact factor: 4.256

Review 5.  Variability in laboratory parameters used for management of Cushing's syndrome.

Authors:  Francesca Pecori Giraldi; Alberto G Ambrogio
Journal:  Endocrine       Date:  2015-07-10       Impact factor: 3.633

6.  Association between posttest dexamethasone and cortisol concentrations in the 1 mg overnight dexamethasone suppression test.

Authors:  Bjørn O Asvold; Valdemar Grill; Ketil Thorstensen; Marit R Bjørgaas
Journal:  Endocr Connect       Date:  2012-08-30       Impact factor: 3.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.